eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering the discovery and development of a new class of oncology drugs known as selective translation regulators (STRs).
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
08/24/2017 | Series C | $39.1MM | $xx.xx | $197.73MM | Abbvie Biotech Ventures, Abingworth, Alexandria Venture Investments, Altitude Life Science Ventures, Astellas Ventures, Biomed Ventures, Novartis Venture Fund, Pfizer Venture Investments, Sectoral Asset Management, Sr One, The Column Group, U.S. Venture Partners | |
Price per Share
$xx.xx
Shares Outstanding
76,070,076
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Abbvie Biotech Ventures, Abingworth, Alexandria Venture Investments, Altitude Life Science Ventures, Astellas Ventures, Biomed Ventures, Novartis Venture Fund, Pfizer Venture Investments, Sectoral Asset Management, Sr One, The Column Group, U.S. Venture Partners
|
||||||
12/22/2015 | Series B | $56MM | $xx.xx | $141.22MM | Abbvie Biotech Ventures, Abingworth, Altitude Life Science Ventures, Astellas Ventures, Biomed Ventures, Mission Bay Capital, Novartis Venture Fund, Osage University Partners, Sr One, The Column Group, Us Venture Partners | |
Price per Share
$xx.xx
Shares Outstanding
114,646,041
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Abbvie Biotech Ventures, Abingworth, Altitude Life Science Ventures, Astellas Ventures, Biomed Ventures, Mission Bay Capital, Novartis Venture Fund, Osage University Partners, Sr One, The Column Group, Us Venture Partners
|
||||||
05/20/2013 | Series A | $56.98MM | $xx.xx | $67.04MM | Abingworth, Astellas Venture Management, Mission Bay Capital, Novartis Venture Funds, Osage University Partners, Sr One, U.S. Venture Partners | |
Price per Share
$xx.xx
Shares Outstanding
145,560,097
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
11.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Abingworth, Astellas Venture Management, Mission Bay Capital, Novartis Venture Funds, Osage University Partners, Sr One, U.S. Venture Partners
|